Current Report Filing (8-k)
March 17 2016 - 4:38PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 11, 2016
BIOSCRIP, INC.
(Exact name of Registrant as specified in
its charter)
Delaware |
|
000-28740 |
|
05-0489664 |
(State of Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
1600 Broadway, Suite 950, Denver, Colorado |
|
80202 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (720) 697-5200
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Section 7 – Regulation FD
Item 7.01. Regulation FD Disclosure.
As previously disclosed by BioScrip,
Inc. (the “Company”) in the Company’s Annual Report on Form 10-K filed on March 3, 2016, Walgreen Co. and
various affiliates (“Walgreens”) filed a lawsuit on November 3, 2015, in the Delaware Court of Chancery (the
“Court”) against the Company and certain of its subsidiaries (collectively, the “Defendants”). The
complaint alleged in relevant part that the Defendants breached certain non-compete provisions contained in the Community
Pharmacy and Mail Business Purchase Agreement dated as of February 1, 2012, by and among Walgreens and the Company and
certain of their respective subsidiaries (the “Purchase Agreement”). The non-compete provisions in the Purchase
Agreement expire as of May 4, 2017. On December 7, 2015, BioScrip filed a motion to dismiss the complaint, asserting, among
other things, that the claims raised in Walgreens’ Complaint were subject to the alternative dispute resolution
procedure contained in the Purchase Agreement.
On March 11, 2016, the Court held oral argument
on the Company’s motion to dismiss and granted the motion, holding that Walgreens’ breach of contract claims for money
damages must be resolved in accordance with the Purchase Agreement’s alternative dispute resolution procedure. On March 15,
2016, Walgreens informed the Court that it would not be pursuing any claims for injunctive relief in the Court, but instead would
engage in the required alternative dispute resolution procedure. Walgreens requested that the Court keep the case open pending
the results of that process. On March 16, 2016, the Court stayed the lawsuit and removed the trial from its calendar, but did not
grant Walgreens any other relief or enjoin the Company from taking any action. Although there can be no guarantee as to the outcome
of this matter, the Company continues to believe that Walgreens’ claims are without merit and intends to vigorously defend
itself against them.
As provided in General Instruction B.2
to Form 8-K, the information furnished in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under
that Section and shall not be deemed incorporated by reference into any filing of the Company with the Securities and Exchange
Commission under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly provided by specific
reference in such filing.
Forward-Looking Statements - Safe Harbor
This Current Report on Form 8-K includes
statements that may constitute “forward-looking statements” conveying management’s expectations as to the future
based on current plans, estimates and projections. These statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. You can identify these statements by the fact that they do not relate strictly to historical
or current facts. In some cases, forward-looking statements can be identified by words such as “may,” “should,”
“could,” “anticipate,” “estimate,” “expect,” “project,” “intend,”
“plan,” “believe,” “predict,” “potential,” “continue” or comparable
terms. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and, because such
statements inherently involve risks and uncertainties, including how a court adjudicates the Complaint, actual results may differ
materially from those in the forward-looking statements as a result of various factors. Investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date hereof.
Important factors that could cause or contribute
to such differences include but are not limited to risks associated with the uncertainty of the outcome of the lawsuit, as well
as the other risks in the Company’s periodic filings with the Securities and Exchange Commission. The Company does not undertake
any duty to update these forward-looking statements after the date hereof even though the Company’s situation may change
in the future, except as required by law. All of the forward-looking statements herein are qualified by these cautionary statements.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BIOSCRIP, INC. |
|
|
Date: March 17, 2016 |
|
/s/ Kathryn M. Stalmack |
|
By: |
Kathryn M. Stalmack |
|
|
Senior Vice President, Secretary and General Counsel |
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Apr 2023 to Apr 2024